Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 25% ± 8% | |
adipocyte | 9 studies | 30% ± 10% | |
oligodendrocyte | 8 studies | 24% ± 7% | |
glutamatergic neuron | 6 studies | 40% ± 25% | |
epithelial cell | 6 studies | 33% ± 15% | |
macrophage | 6 studies | 25% ± 8% | |
microglial cell | 5 studies | 22% ± 5% | |
myeloid cell | 5 studies | 22% ± 4% | |
ciliated cell | 5 studies | 22% ± 7% | |
astrocyte | 5 studies | 29% ± 9% | |
retinal pigment epithelial cell | 4 studies | 36% ± 16% | |
cardiac muscle cell | 4 studies | 22% ± 4% | |
GABAergic neuron | 4 studies | 44% ± 20% | |
type I pneumocyte | 4 studies | 23% ± 5% | |
interneuron | 4 studies | 34% ± 23% | |
hematopoietic precursor cell | 3 studies | 18% ± 1% | |
squamous epithelial cell | 3 studies | 46% ± 23% | |
hepatocyte | 3 studies | 35% ± 22% | |
oligodendrocyte precursor cell | 3 studies | 25% ± 6% | |
abnormal cell | 3 studies | 25% ± 11% | |
monocyte | 3 studies | 19% ± 3% | |
club cell | 3 studies | 22% ± 5% | |
alveolar macrophage | 3 studies | 25% ± 7% | |
endothelial cell of lymphatic vessel | 3 studies | 24% ± 6% | |
fibroblast | 3 studies | 25% ± 4% | |
pericyte | 3 studies | 24% ± 8% | |
smooth muscle cell | 3 studies | 19% ± 1% | |
lymphocyte | 3 studies | 21% ± 4% | |
goblet cell | 3 studies | 30% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 7324.19 | 21 / 21 | 100% | 48.66 | 504 / 504 |
esophagus | 100% | 8347.50 | 1445 / 1445 | 100% | 58.83 | 183 / 183 |
liver | 100% | 6292.48 | 226 / 226 | 100% | 39.92 | 406 / 406 |
lung | 100% | 8610.12 | 578 / 578 | 100% | 58.93 | 1155 / 1155 |
ovary | 100% | 5536.24 | 180 / 180 | 100% | 41.69 | 430 / 430 |
prostate | 100% | 7714.32 | 245 / 245 | 100% | 35.16 | 502 / 502 |
skin | 100% | 8456.02 | 1809 / 1809 | 100% | 69.16 | 472 / 472 |
stomach | 100% | 6362.84 | 359 / 359 | 100% | 41.23 | 286 / 286 |
uterus | 100% | 7089.33 | 170 / 170 | 100% | 54.78 | 459 / 459 |
thymus | 100% | 6895.47 | 653 / 653 | 100% | 34.42 | 604 / 605 |
breast | 100% | 7368.89 | 459 / 459 | 100% | 51.04 | 1116 / 1118 |
intestine | 100% | 7434.02 | 966 / 966 | 100% | 41.78 | 526 / 527 |
brain | 99% | 4548.33 | 2626 / 2642 | 100% | 39.71 | 705 / 705 |
pancreas | 100% | 4589.15 | 327 / 328 | 99% | 39.92 | 177 / 178 |
kidney | 100% | 7972.80 | 89 / 89 | 99% | 42.22 | 893 / 901 |
adrenal gland | 100% | 9602.90 | 258 / 258 | 99% | 35.51 | 227 / 230 |
adipose | 100% | 7776.42 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 8546.34 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 51.28 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 60.85 | 29 / 29 |
muscle | 100% | 20071.10 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 9338.15 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 55.94 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 22.52 | 1 / 1 |
heart | 100% | 7031.96 | 858 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 5794.21 | 904 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030970 | Biological process | retrograde protein transport, ER to cytosol |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0039536 | Biological process | negative regulation of RIG-I signaling pathway |
GO_0032480 | Biological process | negative regulation of type I interferon production |
GO_0007030 | Biological process | Golgi organization |
GO_0036503 | Biological process | ERAD pathway |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0036501 | Cellular component | UFD1-NPL4 complex |
GO_0042175 | Cellular component | nuclear outer membrane-endoplasmic reticulum membrane network |
GO_0005654 | Cellular component | nucleoplasm |
GO_0034098 | Cellular component | VCP-NPL4-UFD1 AAA ATPase complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0036435 | Molecular function | K48-linked polyubiquitin modification-dependent protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0051117 | Molecular function | ATPase binding |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | NPLOC4 |
Protein name | NPL4 homolog, ubiquitin recognition factor Nuclear protein localization protein 4 homolog (Protein NPL4) |
Synonyms | NPL4 KIAA1499 |
Description | FUNCTION: The ternary complex containing UFD1, VCP and NPLOC4 binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope (By similarity). Acts as a negative regulator of type I interferon production via the complex formed with VCP and UFD1, which binds to RIGI and recruits RNF125 to promote ubiquitination and degradation of RIGI . . |
Accessions | I3L4S2 ENST00000572824.1 K7EJN1 ENST00000570324.1 I3L3I1 ENST00000572760.5 A0A0D9SFI9 ENST00000625705.1 ENST00000571714.5 A0A994J7H4 ENST00000705719.1 Q8TAT6 I3L281 ENST00000573212.5 ENST00000574897.5 ENST00000573876.1 I3L4U9 ENST00000573519.5 ENST00000331134.11 [Q8TAT6-1] I3L283 I3L0W3 ENST00000374747.9 [Q8TAT6-2] |